Integra LifeSciences reports Q3 results, cites flood impact and cuts Q4 revenue outlook

Integra LifeSciences posted third‑quarter 2026 revenue of $411.2 million, up 2.3% year‑over‑year, but said a Cincinnati flood removed about $7 million of sales. The company completed a $2.1 billion debt refinancing after the quarter. It lowered its fourth‑quarter revenue forecast to $413 million‑$433 million, a decline of 0.5%‑5.2% versus the prior year, and reaffirmed full‑year revenue guidance of $1.634 billion‑$1.654 billion.

The reduced Q4 revenue range sits below analyst consensus of $432.21 million, which may pressure the stock price (the company’s own guidance notes the shortfall)【12】. The refinancing adds roughly $8 million of interest expense in Q4, affecting near‑term earnings outlook【17】.

  • 1Q3 2026 revenue was $411.2 million, a 2.3% increase YoY
  • 2The results included an approximate $7 million revenue impact from Cincinnati flood damage
  • 3Adjusted EPS for Q3 was $0.59
  • 4Integra completed a $2.1 billion debt refinancing on October 19, 2026
  • 5Q4 2026 revenue guidance was revised to $413 million‑$433 million, representing a reported decline of 0.5%‑5.2% YoY
  • 6Full‑year 2026 revenue guidance remains $1.634 billion‑$1.654 billion

Sources